Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China, Japan Sign Agreement to Share Marrow Donation Information (China)

This article was originally published in PharmAsia News

Executive Summary

The Chinese Marrow Donor Program (CDMP) has partnered with Japan's bone marrow bank as of Sept. 25. The two organizations are dedicated to pooling their resources in an effort to find more cell donors for leukemia patients. China's database currently contains 670,000 donors while Japan's boasts 280,000. By combining, both groups hope to significantly increase the chances of finding hematopoietic stem cells that match those of leukemia patients. Currently, China has over one million leukemia patients, a number that is growing by about 40,000 people annually. Japan also has over 2,000 patients awaiting hematopoietic stem cells. The CDMP has already created similar alliances with the U.S., South Korea, and Singapore, and donated 11 sets of stem cells to patients in those countries. (Click here for more - May Require Free Registration

You may also be interested in...

China Preps For First COVID Vaccine Roll-Outs

Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers. 

QUOTED. 3 December. Jessica Schubel.

A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.

Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing

Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts